ADELAIDE, Australia, and CAMBRIDGE, Mass., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in ...

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 8, 2026-Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage ...

The study also clarifies the functional role of the receptor's conserved sodium-binding pocket, showing that sodium egress strongly promotes activation-related conformational states, including a ...

Please provide your email address to receive an email when new articles are posted on . Change from baseline in gait variability did not differ between groups, regardless of cognitive load. Treatment ...

Boehringer Ingelheim Pharma GmbH & Co. KG has disclosed dioxane derivatives acting as mGluR4 negative allosteric modulators reported to be useful for the treatment of neurodegeneration, metabolic ...

Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be useful for the treatment of psychiatric ...

Please provide your email address to receive an email when new articles are posted on . A Swiss biopharmaceutical company announced its launch with $63 million in Series A financing for research and ...

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule ...

Neuphoria’s social anxiety disorder program will be discontinued based on the results from the AFFIRM-1 trial. Topline results were announced from a phase 3 trial evaluating BNC210 in patients with ...